Needham & Company LLC Reaffirms Buy Rating for Hologic (NASDAQ:HOLX)

Needham & Company LLC reiterated their buy rating on shares of Hologic (NASDAQ:HOLX) in a research note released on Thursday, Briefing.com Automated Import reports. They currently have a $57.00 price objective on the medical equipment provider’s stock, up from their prior price objective of $52.00.

Several other research analysts also recently commented on the stock. BidaskClub upgraded shares of Hologic from a hold rating to a buy rating in a research report on Saturday, July 27th. ValuEngine upgraded shares of Hologic from a hold rating to a buy rating in a research report on Tuesday, June 11th. TheStreet downgraded shares of Hologic from a b rating to a c+ rating in a research report on Wednesday, May 1st. BTIG Research restated a buy rating and set a $52.00 price objective on shares of Hologic in a research report on Thursday, May 2nd. Finally, Zacks Investment Research upgraded shares of Hologic from a hold rating to a buy rating and set a $46.00 price objective for the company in a research report on Wednesday, May 29th. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating and five have assigned a buy rating to the company. The stock presently has a consensus rating of Hold and a consensus price target of $46.77.

Shares of HOLX stock traded down $0.58 during trading on Thursday, hitting $50.25. The company had a trading volume of 1,535,067 shares, compared to its average volume of 1,961,195. The company has a quick ratio of 1.02, a current ratio of 1.57 and a debt-to-equity ratio of 1.27. The company has a market cap of $13.59 billion, a price-to-earnings ratio of 22.53, a P/E/G ratio of 2.34 and a beta of 0.74. The stock’s 50-day simple moving average is $48.47. Hologic has a one year low of $37.47 and a one year high of $52.19.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 31st. The medical equipment provider reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.61 by $0.02. Hologic had a positive return on equity of 27.95% and a negative net margin of 0.89%. The business had revenue of $852.40 million during the quarter, compared to analysts’ expectations of $836.91 million. During the same period in the previous year, the company posted $0.58 earnings per share. The firm’s revenue for the quarter was up 3.4% compared to the same quarter last year. On average, analysts predict that Hologic will post 2.43 EPS for the current year.

In other news, insider Peter J. Valenti III sold 4,545 shares of the company’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $44.07, for a total transaction of $200,298.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.90% of the stock is currently owned by corporate insiders.

Several large investors have recently made changes to their positions in the company. Qube Research & Technologies Ltd acquired a new stake in Hologic in the second quarter valued at $591,000. Comerica Bank increased its holdings in Hologic by 2.2% in the second quarter. Comerica Bank now owns 58,099 shares of the medical equipment provider’s stock valued at $2,750,000 after purchasing an additional 1,239 shares during the period. Envestnet Asset Management Inc. increased its holdings in Hologic by 13.0% in the second quarter. Envestnet Asset Management Inc. now owns 48,530 shares of the medical equipment provider’s stock valued at $2,330,000 after purchasing an additional 5,573 shares during the period. Candriam Luxembourg S.C.A. increased its holdings in Hologic by 116.7% in the second quarter. Candriam Luxembourg S.C.A. now owns 156,569 shares of the medical equipment provider’s stock valued at $7,485,000 after purchasing an additional 84,328 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its holdings in Hologic by 33.5% in the second quarter. DekaBank Deutsche Girozentrale now owns 363,741 shares of the medical equipment provider’s stock valued at $17,399,000 after purchasing an additional 91,351 shares during the period. Institutional investors own 96.45% of the company’s stock.

About Hologic

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Recommended Story: What does cost of debt say about a company’s financial health?

Analyst Recommendations for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.